Lift Vancouver 2023 is to be held at the Vancouver Convention Center from January 12-14, 2023. Lift is a leading event-organizing company engaged in organizing high-quality cannabis events in North America, each of which is curated and designed for multiple audiences within the cannabis industry and community. The event is a grand forum for both established and new businesses, offering them the opportunity to gain visibility in the wider cannabis spectrum and the chance at discovery by investors, partners and media.

Attended by cannabis industry stalwarts and fresh voices alike, this coveted event showcases the presence of cannabis businesses, growers, entrepreneurs, regulators and innovators, as well as cannabis enthusiasts. But there’s more to Lift than just business. Enjoy unique activations (think games, photo opps and more), plus music, giveaways and an after party where attendees can connect with the industry in an informal setting.

Lift Vancouver 2023 will begin with the Lift Cannabis Business Conference on January 12, 2023, a premier conference that features top industry leaders and experts who will share cutting-edge knowledge-based sessions. Attendees can gain a wealth of information and learn new strategies about the latest offerings in the world of the cannabis trade through these valuable speaker sessions. From health to recreation, all facets of the cannabis trade and industry will be explored at the conference.

The trade show then commences from January 13-14, 2023, where hundreds of exhibiting companies will showcase their offerings. It’s the ideal setting for the cannabis community to learn about the latest products being launched in the market, as well as compare technology and preview new innovations.  Also, two new neighborhoods, a Brand Discovery Pavilion and Cannabis Retailer Zone, will bring novel experiences to budtenders and consumers.

Speaking of budtenders, another highlight of the Lift event is the Lift Budtender Program, celebrating these under-recognized cannabis industry members. The event will offer budtenders perks including free entry to the show (with verified certificate number) and a dedicated lounge area with giveaways and refreshments.

Lift Vancouver 2023 tickets are on sale now. To learn more and purchase tickets, visit https://liftexpo.ca/lift-co-expo-vancouver-2023/.

Mining leaders and professionals, policymakers, regulators, investors, and educators, are invited to the Resourcing Tomorrow – Mines and Money London conference, being held November 29 – December 1, 2022, at the Business Design Centre, London. The topics to be covered by experts are dedicated to global sustainability goals, including energy transition, ESG, decarbonization, and the circular economy. Mines and Money London is Europe’s leading conference that offers valuable insights into mining, energy and sustainability. witness 2000 attendees with 150+ businesses pitching their goals and ideas in front of 500+ potential investors. Be a part of the 120 talks, panel discussions and keynote presentations. Connect with industry leaders for meaningful interactions and robust networking across the three days. Some giant companies involved in the conference include Rio Tinto, Alcoa, Barrick, Ma’aden, and Anglo-American. As we enter a transitional age where world leaders need to rethink, assess and redesign political, social and economic strategies, be a part of these important business decisions and strategies being laid out at Resourcing Tomorrow. Every year, global leaders from the mining and energy spectrum participate in these conferences to learn and understand the latest offerings, and trends and look out for business opportunities. Some important topics at the conference:

• How the mining industry can contribute to transitioning energy to a green economy
• Discovering and embracing new methods into business such as digitalization, AI, mineral processing, tailings and water management
• As ESG moves from strategy to implementation discussion on topics like ESG metrics, SDPs, and better community engagement becomes vital
• Exploration of geopolitical perspective by addressing supply chain disruption, the impact of the war in Ukraine and resource nationalism issues

Mines and Money is dedicated to providing this international forum where organizers curate the events so that industry leaders and all attendees have access to quality content. They interact, discuss, collaborate, and develop long-term business ties. These participants and leaders include C-suite, Vice Presidents, Heads and Managers of mining companies from all levels. Newbies and budding mining and energy industries can leverage investor opportunities to connect with leading investors, financiers, and industry professionals from across the globe. World-renowned analysts and mining industries will grace the occasion and offer their expert opinion and suggestions on important topics. To learn more, please visit https://ibn.fm/JQkra.

• REZYFi is a Miami, Florida-headquartered growth mortgage origination and specialized financing company that primarily targets licensed and permitted cannabis companies and owners of real estate who lease to cannabis companies
• Traditional banks are governed by federal law, which criminalizes marijuana; as a result, they are hesitant to offer financial services to cannabis businesses
• The President recently set a process in motion that could culminate in the rescheduling of marijuana, although given that this review will not actually decriminalize the substance, the status quo, which disadvantages cannabis companies, will remain
• REZYFi believes cannabis-related companies will continue to experience difficulties accessing financing from traditional banks, presenting a major opportunity

Last month, the President called for marijuana rescheduling by directing the Secretary of Health and Human Services and the Attorney General to “initiate the administrative process to review expeditiously how marijuana is scheduled under federal law” (https://ibn.fm/BV6RE). Currently, marijuana is classified in Schedule 1 of the Controlled Substances Act of 1970, a category reserved for drugs that, according to the US Drug Enforcement Administration (“DEA”), have a high potential for abuse with no accepted medical use (https://ibn.fm/WyVsr). In rationalizing his October 6 announcement, the President noted that “this is the same schedule as for heroin and LSD, and even higher than the classification of fentanyl and methamphetamine – the drugs that are driving our overdose epidemic.” As consequential as the announcement might be, a recent article in MJBizDaily notes that this order has unleashed “a very long, very complex, and very unpredictable force on the world that might yet wreak unintended havoc” (https://ibn.fm/jyJth). This is because of the many unknowns associated with the move. For instance, it could enable struggling American marijuana firms to enjoy tax relief under Section 280E of the federal tax code. At the same time, however, large pharmaceutical companies could be incentivized to enter the cannabis industry, usurping business from existing but smaller players. Moreover, at a legislative level, an act of Congress could cancel out the recommendations that emerge from the review process. And even if the rescheduling were successful, there are cons associated with each new schedule under which marijuana could be classified. For instance, the MJBizDaily article notes, rescheduling marijuana as a Schedule 2 drug will mean that cannabis companies will have to endure the arduous and expensive FDA approval process before their products can enjoy legal relief. Moreover, a new Schedule 3 or 4 status will still require FDA approval even though the cannabis industry is not designed to comply with it. Finally, reclassification to Schedule 5 will only permit marijuana’s use for medical purposes and not responsible recreational use. Nevertheless, regardless of whichever schedule marijuana falls under post-rescheduling, the review, as is, will not decriminalize the substance. And as a result, the status quo, which sees cannabis-related companies struggle to obtain financing from traditional banks, may remain. (Traditional banks abide by federal law, which currently criminalizes marijuana use.) This presents a gap that REZYFi and its wholly owned subsidiaries, REZYFi Lending and ResMac, have sought to fill. In fact, REZYFi believes cannabis-related firms will continue to experience difficulties obtaining financing from traditional sources – the rescheduling efforts notwithstanding – creating opportunity for the company. REZYFi is a growth mortgage origination and specialized financing company headquartered in Miami, Florida. The company primarily offers a variety of real-estate-related first and additional mortgage-based financing and project-specific financings to licensed and permitted cannabis companies and owners of real estate who lease to cannabis companies. Through REZYFi Lending, the company provides specialty lending, cannabis commercial lending, and cannabis working capital letter of credit (“LOC”). On the other hand, it offers correspondent, retail, and wholesale mortgages through ResMac. REZYFi believes the demand for innovative financing offerings by players in the cannabis market will continue to grow as more geographic markets legalize recreational and medical cannabis usage, a belief that has fueled its expansion within the United States. Currently, REZYFi is licensed in 36 states but is looking to expand into additional jurisdictions. For more information, visit the company’s website at www.REZYFi.com. NOTE TO INVESTORS: The latest news and updates relating to REZYFi are available in the company’s newsroom at https://ibn.fm/REZY

• SideChannel recently released Enclave, its first software product
• The company acquired SideChannel in July 2022 and changed its name post-acquisition
• An industry benchmark study puts average CISO compensation at $463,000 annually, making SideChannel’s vCISO model attractive to its SMB target market
• According to IBM, the average cost to organizations of a cybersecurity breach is $4.2 million
• Cybersecurity Ventures reports a lack of trained professionals will leave 3.5 million cybersecurity positions unfilled by 2025, increasing demand for virtual security services

SideChannel (OTCQB: SDCH) simplifies cybersecurity for mid-market companies by matching them with highly experienced information security officers at a cost lower than building an in-house information security team or hiring a full-time CISO. SideChannel’s team of virtual Chief Information Security Officers (“vCISOs”) possesses a combined 400-plus years of experience in cybersecurity. They’ve honed their skills and abilities in places like Anthem, Dick’s Sporting Goods, Best Buy, TD Bank and the Pentagon. SideChannel lends this talent to clients, creating value in the form of a bespoke cybersecurity program perfectly sized for the growing enterprise. SideChannel is committed to creating top-tier cybersecurity programs for SMBs to help them protect their data and assets. To date, SideChannel has created more than 50 multi-layered cybersecurity programs for its clients. Reports show that cyberattacks on SMBs have increased in recent years, as organizations’ network attack surfaces have grown exponentially with remote and in-office workers increasingly relying on cloud environments, mobile devices, software applications and third-party suppliers to conduct business. SideChannel continues expanding its service offerings, workforce and customer base, attracting over 20 virtual CISOs to serve across industries including fintech, biotech, healthcare, manufacturing, legal, defense and technology services. The company is based in Worcester, Massachusetts. Market Opportunity An analysis from ReportLinker states that the global cybersecurity market is expected to grow from an estimated value of $173.5 billion in 2022 to $266.2 billion by 2027, recording a CAGR of 8.9% for the period. The increased number of data breaches worldwide, the ability of malicious actors to operate from anywhere in the world, the links between cyberspace and physical systems, and the difficulty of reducing vulnerabilities and consequences in complex cyber networks are some factors driving cyber security market growth, according to the report. A lack of cybersecurity professionals and the budget constraints among SMBs and start-ups in developing economies are expected to hinder market growth. Cybercriminals are using automated techniques to attack SMBs’ networks to take advantage of their weak security infrastructures. To save money, time and resources, SMBs are seeking cybersecurity solutions. Enclave Enclave expands upon SideChannel’s cybersecurity service offerings by solving a pervasive network security problem with a simple tool. A comprehensive cloud and network security solution, Enclave enables IT teams to contain breaches faster, reduce network outages, minimize latency and strengthen overall security defense. Enclave creates the foundation for a Zero Trust network security model IT can build upon. With Enclave, IT can easily segment their company’s network, organize personnel and computing devices at the employee workload level, and implement security controls across all network segments. Enclave was designed and purpose built to serve the growing security needs of SMBs, a traditionally underserved market that is more prone to cyberattacks but has limited protection due to smaller budgets, inadequate IT security staffing and a lack of cybersecurity awareness among top executives. Enclave is an affordable and effective network security solution that shrinks the attack surface area exposed to a cyber intruder and significantly reduces the amount of effort required to operate securely. Management Team Brian Haugli is CEO of SideChannel. He has led programs for the U.S. Department of Defense, the Pentagon, and Fortune 500 companies. He is an expert on National Institute of Standards and Technology guidance, threat intelligence implementations and strategic organizational initiatives. He is a professor at Boston College, Woods College of Advancing Studies Master’s Program in Cybersecurity. He is also a contributing author for the Wiley book ‘Cybersecurity Risk Management’. Ryan Polk is CFO at SideChannel. He has been the principal of Perissos Partners, an executive consulting firm, since June 2017. He also served in executive roles in the portfolio companies owned by Lacy Diversified, with combined revenue approaching $2 billion. He served as the Vice President for Corporate Financial Planning and Analysis for Brightpoint, a publicly traded, Fortune 500 mobile device logistics company. He earned a bachelor’s degree in accounting and industrial management from Purdue University. Nicholas Hnatiw is Chief Technology Officer at SideChannel. Prior to joining the company, he served as the technical director for network operations supporting U.S. Cyber Command, U.S. Intelligence Agencies and other Department of Defense research organizations. He was also the CEO of Loki Labs, a cyber security firm. He earned a bachelor’s degree in computer engineering and computer science at the University of Massachusetts, Amherst. Bill Roberts is SideChannel’s CISO. He most recently served as the vice president, IS & CISO for Hologic Inc., a global medical device company, where he established cyber security and IT compliance programs. Prior to Hologic, he was vice president of information security for Cytyc Corporation, which was acquired by Hologic in 2007. At Cytyc, he managed global IT as the company grew from 140 employees to 1,500 and from $40 million in revenue to over $750 million. For more information, visit the company’s website at www.SideChannel.com. NOTE TO INVESTORS: The latest news and updates relating to SDCH are available in the company’s newsroom at https://ibn.fm/SDCH

• With the recently passed Inflation Reduction Act, Correlate looks to achieve significant net gains
• The company just posted a significant revenue bump from $236,690 in Q2 2022 to $2,313,577 in Q3 2022, plus shows project opportunities of up to $194 million
• Todd Michaels, Correlate’s CEO, has also noted the company’s finalized M&A plans through Q2 2023, integral to scaling up the size and overall value of its projects and further growing revenue
• In September, the company entered into a non-binding letter of intent to acquire Vermont-based Aegis Renewable Energy Inc., which, once finalized, will present Correlate with new strategic abilities to explore the bludgeoning Northeast renewable energy market

Correlate Infrastructure Partners (OTCQB: CIPI), a tech-enabled development, finance, and fulfillment platform for distributed energy solutions across North America, just released its financial report for the third quarter of the 2022 financial year (“Q3 2022”). Of obvious note was the significant bump in revenue from $236,690 in Q2 2022 to $2,312,577. While speaking during the announcement, Todd Michaels, Correlate’s CEO, lauded the company’s performance and expressed his optimism for the company’s future, particularly with the enactment of the Inflation Reduction Act (https://ibn.fm/wVfqP). Mr. Michaels acknowledged the Act, citing its benefits to clients and investors in the renewable energy space, reporting that the move will be a significant net gain for the company and integral in opening it up to new markets in 2023. “The Inflation Reduction Act enacted in late August provided new tax incentives that reduce costs for clients and/or elevate returns to investors; this led to larger contract sizes with redesigns to domestic content,” noted Mr. Michaels. “While this meant delaying some project starts, it will be a big net gain, and will open new markets for us in 2023,” he added. The Inflation Reduction Act was designed to offer renewable technologies tax credits. While it promises immediate results and benefits, the most significant impact is projected to be felt toward the end of the decade once supply-chain issues are fixed. For example, through this Act, it is estimated that solar power plants built between 2022 and 2030 will generate over 364 gigawatts of electricity, which is more than three times the capacity of all US solar plants in operation in 2021 (https://ibn.fm/Gupzo). Currently, Correlate has project opportunities valued at up to $194 million, with projects in development that have been awarded agreements and contracts that have been executed and are under installation. With the implemented Act, it looks to significantly scale up its projects’ size and overall value, ultimately growing its revenue and creating even more value for its shareholders. This will also be achieved by Correlate’s ambitious M&A plan, which Mr. Michaels notes the company has already finalized. “With this in mind [anticipated project delays], we have finalized our M&A plans through Q2 2023 and seek to close our first acquisition by year-end,” noted Mr. Michaels. In September, Correlate entered into a non-binding letter of intent to acquire Vermont-based Aegis Renewable Energy Inc., a leading commercial, industrial, and community solar company focused on solar project development and engineering, procurement, and construction (“EPC”). Through this acquisition, Correlate hopes to capitalize on new strategic abilities to explore the bludgeoning Northeast renewable energy market where some of the states in the region, such as Vermont, have set goals to meet 90% of their energy needs with renewable sources by 2050 (https://ibn.fm/f5DuI). Correlate remains optimistic about its performance going forward and looks to capitalize on new and existing opportunities to achieve its short-term and long-term goals. Mr. Michaels is confident that the recently-implemented Inflation Reduction Act will play an integral role in the company’s growth, expansion of its opportunity pipeline, and value creation for its shareholders. For company information, visit the company’s website at www.CorrelateInfra.com, including the following:

• Breaking Down Barriers To Your ESG Goals While Generating Additional Net Operating Income www.CorrelateInfra.com/our-process
• Platform Generates New Rent And Operating Income, Allowing You To Meet Your ESG Goals www.CorrelateInfra.com/program

NOTE TO INVESTORS: The latest news and updates relating to CIPI are available in the company’s newsroom at https://ibn.fm/CIPI

• Ammonia is a highly efficient carrier of both hydrogen and nitrogen, with nitrogen being a critical component to fertilizers and world food production, but traditional ammonia production results in large greenhouse gas emissions
• FuelPositive’s carbon-free “green ammonia” production technology represents an environmentally superior way of producing ammonia
• The company’s confidence in its product has seen it go the extra mile to develop on-farm containerized, green ammonia production systems, that can be leveraged on a smaller scale to create green ammonia for agricultural fertilizers on-site

FuelPositive (TSX.V: NHHH) (OTCQB: NHHHF), a company focused on licensing, partnership, and acquisition opportunities related to energy-efficient, climate-safe, and sustainable solutions and sustainability, recognizes the rapidly growing demand for green technologies. The need is formalized in the UN’s 2050 Net Zero Goal for the drastic reduction of greenhouse gas emissions (https://ibn.fm/JXpj9). While there is a warranted push towards solar and wind energy, the company is bringing something new and viable to the discussion: green ammonia. FuelPositive’s green ammonia offers something different, a commercially viable and sustainable green solution for use across various industries and applications such as agriculture, transportation, and energy generation. Ammonia is a highly efficient carrier of both hydrogen and nitrogen. While hydrogen is critical to prospects for a hydrogen economy, nitrogen is a critical component to fertilizers and world food production. However, traditional ammonia production results in large greenhouse gas emissions. FuelPositive’s carbon-free green ammonia production technology offers an innovative alternative solution to the concerns associated with traditional ammonia generation, minimizing greenhouse gas emissions. As a result, it offers technology to address storage problems associated with hydrogen production and use, and technology to allow the production of ammonia for agricultural fertilizers with minimum greenhouse gas emissions. In the field of agriculture, FuelPositive’s confidence in its product has seen it go the extra mile to develop on-farm, containerized, green ammonia production systems that can be leveraged on a smaller scale to create on-site green ammonia. This is a huge step for more environmentally friendly agriculture, since 80% or more of all ammonia produced is used for fertilizing agricultural crops (https://ibn.fm/Yh4xC). For more information, visit the company’s website at www.FuelPositive.com. NOTE TO INVESTORS: The latest news and updates relating to NHHHF are available in the company’s newsroom at https://ibn.fm/NHHHF

• BiondVax summarizes collaboration with the prestigious Max Planck Institute for Multidisciplinary Sciences and the University Medical Center Göttingen to discover and develop nanosized antibody (NanoAb) therapies that address underserved and growing markets, including COVID-19, psoriasis, asthma, psoriatic arthritis and wet macular degeneration.
• The global COVID-19 therapy market was valued at $16.8 billion in 2021 and is expected to grow at a CAGR of 20% during the forecast period, resulting in a value of $35.42 billion by 2025
• The psoriasis market is experiencing a higher-than-expected demand across all regions due to the increasing geriatric population and the growing prevalence of plaque psoriasis and psoriatic arthritis resulting in an anticipated value of $47.24 billion by 2029

Joshua E. Phillipson, BiondVax Pharmaceuticals (NASDAQ: BVXV) Director of Communications and Investor Relations, recently presented the company’s corporate presentation to investors attending the LD Micro Main Event hosted by SRAX, Inc. at the Luxe in Los Angeles and online via Sequire Virtual Events platform October 25-27, 2022. The LD Micro Main Event, known as the “Woodstock” of the micro-cap world, has been showcasing the next big names in the space for the last 15 years. Phillipson was provided with 25 minutes on the main stage to offer investors an in-depth look at the company. The video is available at https://me22.sequireevents.com/recording?session_id=c2bc57cd-a925-43b2-8441-9f927a64b4f7 (free registration required).

BiondVax is a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treatment of infectious diseases and autoimmune diseases. BiondVax is developing a pipeline of innovative nanosized antibody (NanoAb) therapies addressing diseases underserved by current treatments and with large and growing markets, such as COVID-19, psoriasis, asthma, psoriatic arthritis and wet macular degeneration. The company currently collaborates with the prestigious Max Planck Institute for Multidisciplinary Sciences (“MPG”) and the University Medical Center Göttingen (“UMG”), both in Germany.

Phillipson shared the company’s significant potential for value creation with the investors in attendance and online during the LD Micro event. BiondVax is targeting a massive, validated, addressable market with a pipeline of de-risked NanoAbs with a lead candidate to treat COVID-19 as a self-administered inhaled therapy that has a strong competitive edge. With seasoned scientific leadership and state-of-the-art laboratories and GMP biologics manufacturing facility, the company is well-positioned to bring innovative therapies to market with unique large pharma competencies. Key catalysts for BiondVax are expected in 2022 and 2023.

The company is tapping into the markets of multiple indications to create avenues where there is an unmet need for pharmaceutical therapies. The global COVID-19 therapy market was valued at $16.8 billion in 2021 and is expected to grow at a CAGR of 20% during the forecast period, resulting in a value of $35.42 billion by 2025 (https://ibn.fm/qgzIB). Additionally, BiondVax is planning to target the psoriasis treatment market, which was valued at $24.33 billion globally in 2021. This market is projected to grow to $47.24 billion by 2029 at a CAGR of 8.7%. The psoriasis market is experiencing a higher-than-expected demand across all regions due to the increasing geriatric population and the growing prevalence of plaque and psoriatic arthritis (https://ibn.fm/rOSNg).

The company brings significant clinical and commercial advantages to the collaboration with Max Planck including:

• Infectious disease and recombinant protein drug development experience from lab to Phase 3 clinical trial
• Manufacturing quality and international regulatory experience
• A GMP biologics manufacturing facility well suited to NanoAb production
• Top-tier big pharma and biotech leadership experience
• World-class science and access to leading scientists
• NanoAb platform for the development of promising potent therapeutics
• Exclusive rights to exclusive worldwide licenses covering patented NanoAbs and their manufacturing

BiondVax’s de-risked NanoAbs feature a favorable path to market compared to the risks associated with traditional drug treatments. Compared to monoclonal antibodies (“mAbs”) and oral therapies, the company provides multiple crucial advantages that offer convenience and flexibility backed by clinical benefits.

For more information, visit the company’s website at www.BiondVax.com.

NOTE TO INVESTORS: The latest news and updates relating to BVXV are available in the company’s newsroom at https://ibn.fm/BVXV

• The National Brain Tumor Society anticipates that more than 13,000 Americans will receive a GBM diagnosis during 2022, accounting for 49.1% of all primary malignant brain tumors
• CNS announced the first patient in Europe has been enrolled and dosed in the global trial to evaluate Berubicin for the treatment of GBM
• Berubicin is a novel anthracycline and the first to appear to cross the blood-brain barrier
• The global GBM treatment market is expected to reach a value of $4.2 billion by 2028, driven by the increased approval granted by the FDA for novel GBM treatment therapies

CNS Pharmaceuticals (NASDAQ: CNSP), a clinical stage biotechnology company specializing in the development of novel treatments, announced that the first patient in Europe has been enrolled and dosed in France in the company’s ongoing potentially pivotal global trial to evaluate Berubicin for the treatment of recurrent glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. According to the National Brain Tumor Society, more than 13,000 Americans are expected to receive a GBM diagnosis during 2022, which accounts for 49.1% of all primary malignant brain tumors (https://ibn.fm/RKJHr).

CNS Pharmaceuticals has opened 29 clinical sites of the 68 sites selected across the United States, Italy, France, Spain, and Switzerland. The company is planning a non-binding futility analysis, which will be performed after approximately 30 to 50% of all planned patients have completed the primary endpoint at six months which is expected mid-year 2023. The review will include additional evaluation of safety as well as secondary efficacy endpoints, with no pause to enrollment during the interim analysis.

According to CEO John Climaco, the CNS Pharmaceuticals team worked tirelessly to expand its Berubicin clinical trial globally, and the enrolment and dosing of the first patient in France shortly after the opening of the site is a notable accomplishment and confirmation of the team’s commitment to driving the program forward (https://ibn.fm/K9IUE).

“I am pleased with the progress made and remain committed to building on this momentum. We expect to enroll and dose additional patients across our clinical trial sites in Europe and advance toward the much-anticipated inflection point, which is the interim analysis,” Climaco added.

The global GBM treatment market was valued at $2.14 billion in 2020 and is expected to grow at a CAGR of 8.8% and reach an estimated value of $4.2 billion by 2028. The market’s growth is expected to be driven by the increased approval for novel therapies for GBM treatment. The special designation granted by the FDA for investigational new drugs is expected to help expedite the approval process and commercialization of these therapies (https://ibn.fm/ZxByq).

Berubicin is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier (based upon pre-clinical data and limited clinical data) and is currently being evaluated in the potentially pivotal study evaluating efficacy and safety for GBM treatment. This potentially pivotal study is an adaptive, multicenter, open-label, randomized, and controlled study in adult patients with recurrent GBM after the failure of standard first-line therapy. The study’s primary endpoint is Overall Survival (“OS”), an endpoint the FDA has recognized as a basis for approval of oncology drugs when a statistically significant improvement can be shown relative to a randomized control arm.

CNS’s study will compare Berubicin to a standard of care (Lomustine), with a 2 to 1 randomization of patients to receive one of the two drugs. The recently amended protocol expands eligibility to patients who received additional treatments as a form of first-line therapy. The FDA has granted the company Fast Track Designation for Berubicin, enabling more frequent interactions with them to guide expediting the development and review process. The FDA has also granted CNS Orphan Drug Designation, which may provide seven years of marketing exclusivity upon approval of an NDA.

For more information, visit the company’s website at www.CNSPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

The RHK Capital 2022 Disruptive Growth Conference, being held at the offices of Reed Smith in New York City, invites investors, capitalists, life science companies, growth companies and budding enterprises, for an interactive session of learning, networking, exchange of ideas, and business collaborations, spread over two days. The RHK Capital 2022 Disruptive Growth Conference offers a robust forum and an exclusive opportunity to discover disruptive growth companies. Up to 30 senior management teams from highly reputed companies will pitch their businesses to over 200 institutional investors, accredited investors, family offices, Wall Street analysts, financial advisors, broker-dealer wealth managers and RHK Capital clients. The conference commences with registrations on the first day, followed by panel discussions, company presentations, and buffet lunches, followed again by conference events. The RHK 2022 Disruptive Growth Conference offers investors the forum to discover growth companies with disruptive technologies and business models covering the following sectors: communications, consumer, energy/alternative energy, healthcare, industrial, life sciences, natural resources, and technology. Investors can meet the company executives in one-to-one sessions to analyze, assess, and learn about company goals and future aspirations. In the past, many eminent companies and investors have been a part of this show. They continue to visit every year to gain a better business perspective, new clients and opportunities. Budding companies and new entrepreneurs looking for investors can fix personal meetings to discuss their business goals in depth with these industry leaders. The RHK Capital conferences are curated keeping the attendees in mind. The organizers specialize in delivering tailored experiences through these personalized conferences and research-based events. Their educational programming sessions are hosted by dignitaries who guide the attendees and discuss pivotal topics that are expected to shape the future of industries. At this forum, micro-cap companies take the opportunity to make presentations on their goals and future expansion plans, engaging directly with investors through one-on-one discussions, presentations, and dialogues, developing and strengthening business ties. Investors and presenting companies repeatedly join with every event owing to the immense response that they receive. Attendees can be a part of the personalized sessions with industry heavyweights to speak on numerous important business trends and strategies. The event encourages small-cap and micro-cap companies that show growth potential, to connect with investors and build long-term profitable business ties. To know more, please visit https://ibn.fm/eAtz4.

• Vision Energy is in advanced stages of planning for construction and delivery of Northwestern Europe’s first import, storage and handling terminal designed exclusively for hydrogen carriers, renewable energy products and low-carbon fuels
• Vision Energy, through its wholly owned subsidiary Evolution Terminals BV, just announced partnership with Linde Engineering, a leading global industrial gases and engineering company, to deliver preliminary Front-End Engineering and Design (“FEED”) services to the project
• Green Energy Terminal Project will accelerate and advance the energy transition and facilitate Northwestern Europe’s ambition to achieve Net Zero through carbon-abatement and adoption of hydrogen as a core feedstock and fuel

Committed to providing the lowest carbon solutions with the highest yield hydrogen production, Vision Energy (OTCQB: VIHDD) just announced another milestone in the development of the company’s pioneering Green Energy Terminal in North Sea Port of Vlissingen, the Netherlands. In a recent press release Vision Energy reported it has entered into a cooperation agreement with Linde Engineering to accelerate engineering efforts for the company’s pioneering Green Energy Terminal in North Sea Port of Vlissingen, the Netherlands. Linde Engineering, a leading global industrial gases and engineering company with 2021 sales of $31 billion, will deliver preliminary Front-End Engineering and Design (“FEED”) services to the project including design and engineering of 150,000 cubic meters (“CBM”) of Green Ammonia (“NH3”) storage, truck and barge loading facilities, ship loading and unloading facilities, as well as utilities, infrastructure and buildings.

With its strategic location between the Scheldt River and the North Sea, Vlissingen has been an important harbor for centuries and is now an economic driving force serving all of Europe. Vision Energy is in the advanced stages of planning the construction and delivery of Northwestern Europe’s first import, storage and handling terminal designed exclusively for hydrogen carriers, renewable energy products and low-carbon fuels. Total capacity under Phase 1 is for up to 400,000 CBM including 150,000 CBM allocated to Green Ammonia, 180,000 CBM allocated to Renewable Methanol and 70,000 CBM allocated to Biofuels.

“Our Green Energy Terminal Project will accelerate and advance the energy transition and facilitate Northwestern Europe’s ambition to achieve Net Zero through carbon-abatement and adoption of hydrogen as a core feedstock and fuel,” stated Andrew Hromyk, Vision Energy CEO, “Our cooperation with Linde Engineering marks a critical milestone in our development, to deliver this world-class project with the vast global expertise Linde possesses.”

An integrated energy company developing assets and solutions for the commercial, industrial and transportation sectors, Vision Energy leverages a proven track-record to facilitate low-carbon energy production, supply and distribution. The company pursues reliable offtake relationships and operating partnerships with energy industry participants and end users seeking carbon abatements across feedstock and fuels. Vision Energy is committed to providing low carbon energy solutions with the highest yield, and where possible, projects are designed to utilize existing gas and power infrastructure to integrate and facilitate import and or distribution of reduced-carbon energy to domestic and global supply chains.

In a world wracked with rising temperatures and increasing climate challenges, Vision Energy is delivering solutions and opportunity. Development of its Green Energy Terminal in Northwestern Europe will lessen dependence on Russian oil, have a positive impact on the economy and help transition to a carbon free future. Expect to hear lots more about Vision Energy in the months and years to come.

For more information, visit the company’s website at https://visionenergy.com/.

NOTE TO INVESTORS: The latest news and updates relating to VIHDD are available in the company’s newsroom at https://ibn.fm/VIHDD